Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key opinion leaders’ discussion highlights new data and
